Oxalic Acid

Oxalic Acid

SCHEMBL10317843

NCC(=O)NCc1cccc(-c2ccc(N3CCOCC3)cc2)c1.O=C(O)C(=O)O

nearest known ligand 0.65

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

OPRM1SLC6A4

The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ AOC3 Q16853 10/20 0.65
▸ SRC P12931 1/20 0.56
▸ ERCC1 P07992 1/20 0.51
▸ ERCC4 Q92889 1/20 0.51
▸ MAPT P10636 2/20 0.49
▸ KDM4E B2RXH2 1/20 0.49
▸ POLB P06746 1/20 0.49
▸ JAK2 O60674 1/20 0.47
▸ JAK1 P23458 1/20 0.47
▸ TYK2 P29597 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ USP2 O75604 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ CTSL P07711 1/20 0.46
▸ CTSB P07858 1/20 0.46
▸ CTSS P25774 1/20 0.46
▸ CTSK P43235 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11427269 0.97 AOC3 (0.64) AOC3SRCERCC1ERCC4JAK2
Oxalic Acid SCHEMBL10317845 0.83 AOC3 (0.59) AOC3SRCMAPTKDM4EPOLB
SCHEMBL12526733 0.80 AOC3 (0.53) AOC3SRCERCC1ERCC4MAPT
Oxalic Acid SCHEMBL10317816 0.79 AOC3 (1.00) AOC3
SCHEMBL11892904 0.78 AOC3 (0.52) AOC3SRCERCC1ERCC4MAPT
SCHEMBL13253257 0.77 JAK2 (0.68) JAK2JAK1TYK2
SCHEMBL16785090 0.77 AOC3 (0.56) AOC3SRCERCC1ERCC4MAPT
SCHEMBL3722035 0.77 AOC3 (0.62) AOC3MAPTHTT
SCHEMBL12523781 0.76 AOC3 (0.52) AOC3SRCERCC1ERCC4MAPT
SCHEMBL10320681 0.75 AOC3 (1.00) AOC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2479165-B1 GLYCINE COMPOUND ASTELLAS PHARMA INC (JP) 2017-10-25 — — EP disclosed
US-8802679-B2 Glycine compound ASTELLAS PHARMA INC. (JP) 2014-08-12 — — US disclosed
EP-2479165-A1 GLYCINE COMPOUND Astellas Pharma Inc. (JP) 2012-07-25 — — EP disclosed
US-20120184520-A1 GLYCINE COMPOUND ASTELLAS PHARMA INC. (JP) 2012-07-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184520-A1 GLYCINE COMPOUND SLC5A1, AQP1, VAPB AOC3 894/4885SRC 4282/4885ERCC1 2123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback